{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:18:46Z","timestamp":1790245126714,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.revmed.2020.05.016","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T01:49:59Z","timestamp":1594691399000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab and immune thrombocytopenia in adults: The state of knowledge 20\u00a0years later"],"prefix":"10.1016","volume":"42","author":[{"given":"S.","family":"Deshayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mah\u00e9vas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.05.016_bb0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2020.05.016_bb0010","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.4049\/jimmunol.168.7.3675","article-title":"Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura","volume":"168","author":"Kuwana","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0025","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0040","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0045","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0050","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2016.11.002","article-title":"B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia","volume":"77","author":"Audia","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2020.05.016_bb0060","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0065","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2015-06-655126","article-title":"CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia","volume":"127","author":"Guo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0075","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0085","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.016_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2020.05.016_bb0100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0110","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3324\/haematol.2014.110213","article-title":"Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients","volume":"100","author":"Zwaginga","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12185-016-1992-4","article-title":"Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles","volume":"104","author":"Reboursiere","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0125","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.mayocp.2019.05.024","article-title":"Sequence of splenectomy and rituximab for the treatment of steroid-refractory immune thrombocytopenia: does it Matter?","volume":"94","author":"Hammond","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2020.05.016_bb0130","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0135","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0140","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3324\/haematol.2008.001396","article-title":"Slow responses to standard dose rituximab in immune thrombocytopenic purpura","volume":"94","author":"Kelly","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.exphem.2006.02.009","article-title":"Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia","volume":"34","author":"Zaja","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2020.05.016_bb0165","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0170","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2013-03-491415","article-title":"Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia","volume":"122","author":"Audia","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0175","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0180","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2008-02-139402","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0185","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12185-010-0635-4","article-title":"Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients","volume":"92","author":"Aleem","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0195","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-007-0317-3","article-title":"Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis","volume":"86","author":"Garcia-Chavez","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.14782","article-title":"GPIIb\/IIIa autoantibody predicts better rituximab response in ITP","volume":"182","author":"Feng","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0205","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MOH.0b013e3282c8ca50","article-title":"Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?","volume":"14","author":"Cooper","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/10245332.2017.1371479","article-title":"The impact of fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura","volume":"23","author":"Ellithy","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.revmed.2020.05.016_bb0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2141.2012.09184.x","article-title":"Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia","volume":"158","author":"Cooper","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0220","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2016-11-751719","article-title":"Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients","volume":"129","author":"Porcelijn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0225","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.14664","article-title":"The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia","volume":"178","author":"Arnold","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0230","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.23518","article-title":"Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia","volume":"88","author":"Mah\u00e9vas","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11239-008-0208-z","article-title":"The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura","volume":"27","author":"Pasa","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.revmed.2020.05.016_bb0240","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12185-012-1206-7","article-title":"Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice","volume":"96","author":"\u010cervinek","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0245","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01100.x","article-title":"Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results","volume":"81","author":"Medeot","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0250","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00277-006-0123-3","article-title":"Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients","volume":"85","author":"Pe\u00f1alver","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0260","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0265","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0270","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0275","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/107602960601200116","article-title":"Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review","volume":"12","author":"Perrotta","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.revmed.2020.05.016_bb0285","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2020.05.016_bb0290","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2020.05.016_bb0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","article-title":"Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study","volume":"67","author":"Bayer","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2020.05.016_bb0300","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0305","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMcpc0910931","article-title":"Case records of the Massachusetts general hospital case 11-2010 a 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging","volume":"362","author":"Venna","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.016_bb0310","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ajh.25642","article-title":"Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders","volume":"94","author":"Malpica","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0315","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2020.05.016_bb0320","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2016.1138318","article-title":"Late-onset neutropenia after rituximab in ANCA-associated vasculitis","volume":"45","author":"Knight","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0325","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0330","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0b013e3283414edf","article-title":"Neutropenia associated with rituximab therapy","volume":"18","author":"Grant","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0335","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0609.2012.01808.x","article-title":"Rituximab-induced thrombocytopenia: a cohort study","volume":"89","author":"Giezen","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0340","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","article-title":"Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis","volume":"24","author":"Yang","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.revmed.2020.05.016_bb0345","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.16161","article-title":"Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis","volume":"188","author":"Puavilai","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0350","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/09537104.2018.1543864","article-title":"Comparison of treatments for persistent\/chronic immune thrombocytopenia: a systematic review and network meta-analysis","volume":"30","author":"Arai","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.revmed.2020.05.016_bb0355","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2020.05.016_bb0360","series-title":"Protocole national de diagnostic et de soins","article-title":"Purpura thrombop\u00e9nique immunologique de l'enfant et de l'adulte","author":"Fili\u00e8re de sant\u00e9 maladies rares MARIH (Maladies Rares Immuno-H\u00e9matologiques)","year":"2017"},{"key":"10.1016\/j.revmed.2020.05.016_bb0365","author":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM)"},{"key":"10.1016\/j.revmed.2020.05.016_bb0370","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.12448","article-title":"Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study","volume":"162","author":"Liebman","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0375","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2016.146738","article-title":"Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia","volume":"101","author":"Liebman","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.13029","article-title":"A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)","volume":"167","author":"Tran","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0390","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0395","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clinthera.2014.01.017","article-title":"Is splenectomy necessary for immune thrombocytopenic purpura? the role of rituximab in patients with corticosteroid resistance in a single-center experience","volume":"36","author":"Zhang","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.revmed.2020.05.016_bb0400","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.05.016_bb0405","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0410","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0415","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1701-2163(16)34741-7","article-title":"Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura","volume":"32","author":"Gall","year":"2010","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.revmed.2020.05.016_bb0420","doi-asserted-by":"crossref","first-page":"271363","DOI":"10.1155\/2008\/271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0425","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0430","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11926-009-0074-5","article-title":"Use of rituximab in the antiphospholipid syndrome","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2020.05.016_bb0440","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.05.016_bb0445","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.semarthrit.2018.04.001","article-title":"Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome","volume":"48","author":"Sciascia","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.05.016_bb0450","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MEG.0b013e3283249908","article-title":"Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases","volume":"21","author":"Dufour","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0455","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2004.05243.x","article-title":"Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura","volume":"127","author":"Ahmad","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0460","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2020.05.016_bb0465","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-010-0753-z","article-title":"Low-dose rituximab combined with short-term glucocorticoids up-regulates treg cell levels in patients with immune thrombocytopenia","volume":"93","author":"Li","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0475","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0480","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.12102","article-title":"High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia","volume":"90","author":"G\u00f3mez-Almaguer","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0485","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ajh.24434","article-title":"Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia","volume":"91","author":"Chapin","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0490","doi-asserted-by":"crossref","first-page":"1316096","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.revmed.2020.05.016_bb0495","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0500","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2015-03-631937","article-title":"A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)","volume":"126","author":"Choi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0505","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.15070","article-title":"Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia","volume":"184","author":"G\u00f3mez-Almaguer","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.05.016_bb0510","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0515","first-page":"1583","article-title":"Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP","volume":"19","author":"Li","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.revmed.2020.05.016_bb0520","first-page":"2137","article-title":"Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura","volume":"17","author":"Wang","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.revmed.2020.05.016_bb0525","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2010-06-291831","article-title":"Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias","volume":"116","author":"G\u00f3mez-Almaguer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.016_bb0530","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2017.174615","article-title":"Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis","volume":"103","author":"Arai","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.05.016_bb0535","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.revmed.2020.05.016_bb0540","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.016_bb0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:43:05Z","timestamp":1759336985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320302071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0248866320302071"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.05.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab and immune thrombocytopenia in adults: The state of knowledge 20\u00a0years later","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}